Bioceres Crop Solutions Corp logo

Bioceres Crop Solutions Corp(BIOX)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.36
09/28/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for BIOX

09/28/2026: BIOX (1-star) is currently NOT-A-BUY. Pass it for now.

Bioceres Crop Solutions Corp is a specialized agricultural biotechnology company known for its proprietary HB4 drought-tolerant trait technology and biological crop solutions. The company holds a distinct position by focusing on high-growth, sustainable farming innovations that aim to increase productivity in changing climates. Its main growth story is centered on the ongoing global commercialization of its HB4 traits and the expansion of its biological product sales. Investors face notable risks, however, including high geographic concentration, significant regulatory hurdles, and intense competition from large-cap agricultural giants. The stock likely suits growth-oriented investors with a high tolerance for risk and a long-term horizon for market adoption.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to high-growth areas of agricultural technology and biotechnology innovation.
Momentum investorMixed fitMomentum fit is conditional on a sustained positive upturn signal and successful commercial milestones for HB4.
Value investorWeak fitThe stock often trades based on future growth expectations rather than current earnings or book value.
Dividend investorWeak fitThe company does not pay a dividend and is currently focused on capital-intensive growth.
Low-risk investorWeak fitHigh volatility and regulatory risks inherent in ag-tech make this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to significant price swings due to its growth profile and sensitivity to market sentiment.
Valuation riskMedium / highFuture growth is heavily priced in, and valuation may compress if commercial milestones are not met.
Competition risk (Ag-tech giants)HighLarge-cap competitors have greater resources to defend their market share and develop competing traits.
Business qualityMediumWhile the technology is innovative, the company is still establishing consistent long-term profitability.
Dividend incomeLow / noneInvestors should expect no income and must rely entirely on capital appreciation.
Execution riskMedium / highSuccessfully scaling international regulatory approvals and commercial adoption is complex and uncertain.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -38.98%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/28/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BIOX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
BIOX has moderate overall fundamentals (3 stars), with moderate financial health, weak growth momentum, and solid ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-315.6%), soft cash generation (FCF margin 0.0%), negative revenue growth (-28.7%).

Financial Health Rating

★★★★★
BIOX's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 34.6% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BIOX's growth profile is soft, with the least-weak measure being revenue growth at -28.7% FY2026 versus FY2025. By comparison, while earnings growth (-315.6%, negative) and free-cash-flow growth (-100.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 23.1% and approximately 70.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 16.95% supports management-shareholder alignment.

Top 5 Institutional Investors

Solel Partners LP 7.18%
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 1.68%
Long Focus Capital Management, LLC 1.30%
Marshall Wace Asset Management Ltd 1.10%
Ardsley Advisory Partners 0.74%

Unit Economics (Per $1K Revenue)

★★★★★
BIOX generates approximately $347 of gross profit, $0 of operating income, and $0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -6.67% (Tax Credit)

Quantitative Style Profile

★★★★★
BIOX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 23.89M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 447.5K shares
Beta 0.43
52 Weeks Range 0.30 - 2.19
Updated Date 09/28/2026
52 Weeks Range 0.30 - 2.19
Updated Date 09/28/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.74

How Company Makes Money

Business areaWhat it includesRetail investor read
Seed and Integrated ProductsLicensing of HB4 traits and sale of integrated seed solutions.This is the 'high-tech' core of the business, where the potential for recurring licensing revenue lies.
Crop Protection/BiologicalsSales of bio-stimulants, fertilizers, and crop protection chemicals.This provides the company with more stable, recurring cash flow compared to its R&D-heavy segments.
Geography (Latin America)Primary sales and commercial operations in Argentina, Brazil, and surrounding regions.Regional focus means the company is heavily influenced by local economic and climate conditions.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE 14.99
Enterprise Value 249.62M
Price to Sales(TTM) 0.1
Enterprise Value 249.62M
Price to Sales(TTM) 0.1
Enterprise Value to Revenue 1.05
Enterprise Value to EBITDA 17.98
Shares Outstanding 63.82M
Shares Floating 45.01M
Shares Outstanding 63.82M
Shares Floating 45.01M
Percent Insiders 16.95
Percent Institutions 23.13

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI Summary

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Bioceres Crop Solutions Corp

Exchange NASDAQ
Headquarters -
IPO Launch date 2018-03-22
CEO & Executive Director Dr. Federico Trucco Ph.D.
Sector Basic Materials
Industry Agricultural Inputs
Full time employees 751
Full time employees 751

Bioceres Crop Solutions Corp., together with its subsidiaries, develops and commercializes crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Brazil, North America, Europe, the Middle East, South America, the United States, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.